The Europe viral vectors and plasmid DNA manufacturing market was valued at USD 1.81 billion in 2025 and is projected to reach USD 6.71 billion by 2035, expanding at a CAGR of 14%, driven by rising gene therapy demand and biopharma innovation.

Europe Viral Vectors and Plasmid DNA Manufacturing Market Statical Scope

The European viral vector and plasmid DNA manufacturing market is poised for considerable growth over the next decade, fueled by the increasing demand for advanced gene and cell therapy solutions, next-generation vaccines, and pioneering genetic research. Viral vectors and plasmids serve as essential components for the delivery of genetic material into cells, acting as foundational elements in the advancement of genetic medicines utilized in the treatment of inherited disorders, cancers, and infectious diseases. With Europe establishing itself as a key global player in biotechnology innovation and biomanufacturing infrastructure, the market is entering a phase of accelerated expansion.

Europe Viral Vectors and Plasmid DNA Manufacturing Market Share, By Vector Type, 2025 (%)

• Adeno-associated virus (AAV)- Adeno-associated virus (AAV) leads the market, with a share of 30%, driven by its strong safety profile, high efficiency in gene delivery, and rising adoption across gene therapy applications.
• Lentivirus- Lentivirus holds a significant share of 24%, supported by extensive use in cell therapy development and stable transduction performance.
• Adenovirus- Adenovirus represents a segment, with a share of 14%, supported by its role in vaccine development and targeted gene delivery applications.
• Plasmids- Plasmids account for a notable share of 16%, driven by growing demand in DNA-based therapeutics and support for vector manufacturing processes.

Europe Viral Vectors and Plasmid DNA Manufacturing Market Share, By Workflow, 2025 (%)

• Upstream manufacturing- Upstream manufacturing dominates the market, with 58% share, driven by increasing vector production requirements, expansion of cell culture processes, and rising manufacturing capacity investments.
• Downstream manufacturing- Downstream manufacturing holds a share of 42%, supported by the increasing need for purification, processing, and quality assurance activities.

Europe Viral Vectors and Plasmid DNA Manufacturing Market Share, By Application, 2025 (%)

• Gene therapy- Gene therapy leads the market, with a share of 36%, driven by rising clinical development activity and expanding commercialization of gene-based therapies.
• Antisense & RNAi therapy- Antisense & RNAi therapy holds a share of 10%, driven by rising focus on next-generation nucleic acid therapeutics.
• Cell therapy- Cell therapy holds a significant portion, with a share of 22%, supported by rising investment in advanced therapies and growing therapeutic pipelines.
• Vaccinology- Vaccinology accounts for a notable share of 17%, driven by continued demand for vector-based vaccine development and production.
• Research applications- Research applications represent a segment, with a share of 15%, driven by ongoing innovation and preclinical research activities.

Europe Viral Vectors and Plasmid DNA Manufacturing Market Share, By End-use, 2025 (%)

• Pharmaceutical and biopharmaceutical companies- Pharmaceutical and biopharmaceutical companies dominate the market, with a share of 72%, driven by strong outsourcing demand, large-scale production requirements, and expanding therapy pipelines.
• Research institutes- Research institutes hold a significant portion of 28%, supported by ongoing research activity and development of novel vector technologies.

Europe Viral Vectors and Plasmid DNA Manufacturing Market Share, By Disease, 2025 (%)

• Cancer- Cancer leads the market, with a share of 34%, driven by significant focus on oncology-related gene and cell therapy development.
• Genetic disorders- Genetic disorders hold a substantial share of 28%, supported by rising therapeutic development targeting rare and inherited conditions.

Top Companies in the Europe Viral Vectors and Plasmid DNA Manufacturing Market

• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent Inc.
• Wuxi Biologics
• Takara Bio Inc.
• Waisman Biomanufacturing
• Genezen laboratories
• Batavia Biosciences
• Miltenyi Biotec GmbH
• SIRION Biotech GmbH
• Virovek Incorporation
• BioNTech IMFS GmbH
• Audentes Therapeutics
• BioMarin Pharmaceutical
• RegenxBio, Inc.

Segments Covered in the Report

By Vector Type

• Adeno-associated virus (AAV)
• Lentivirus
• Adenovirus
• Retrovirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End Use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others